ALECENSA® (alectinib) Targets ALK+ NSCLC Systemically and in the CNS

ALECENSA is a tyrosine kinase inhibitor that targets ALK and RET 1,9

  • ALECENSA may affect both tumor and normal cells 1,9

Proposed Mechanism of Action for ALECENSA 1,9

ALECENSA was able to cross the blood-brain barrier and remain in the CNS 1,10

  • In vitro studies suggest that ALECENSA is not a substrate of p-glycoprotein, but M4, the major active metabolite of ALECENSA, is a substrate of p-glycoprotein 1
    • P-glycoprotein substrates are typically effluxed from the CNS by p-glycoprotein transporter proteins lining the blood-brain barrier 6

Proposed Distribution in the CNS for ALECENSA 1,9,11-13

The clinical significance of these data is unknown.

1L=first-line; BCRP=breast cancer resistance protein; CNS=central nervous system; M4=major metabolite M4; MRP=multidrug resistance protein; P-gp=p-glycoprotein; PFS=progression-free survival; RET=ret proto-oncogene.

1L PFS Results

View PFS results vs crizotinib from the head-to-head ALEX trial.

CNS Efficacy in 1L ALK+ mNSCLC

Learn more about CNS efficacy with ALECENSA.

Contact a Representative

Contact your local Genentech representative for more information about ALECENSA.